VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESGO 2021 | Improving immunotherapy outcomes in ovarian cancer

Eric Pujade-Lauraine • 24 Oct 2021
ESGO 2021
Gynecological Cancer Ovarian Cancer Bevacizumab
Immuno-Oncology

Eric Pujade-Lauraine, MD, PhD, Hôpital Hôtel-Dieu, Paris, France, outlines approaches to improve outcomes in patients with ovarian cancer treated with immune checkpoint inhibitors, including combinations with chemotherapy as well as bevacizumab. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.

More from Eric Pujade-Lauraine

3:05
Results from the JAVELIN Ovarian 200 biomarker analysis
Eric Pujade-Lauraine • 24 Oct 2021
0:48
Immune checkpoint inhibitors in ovarian cancer
Eric Pujade-Lauraine • 24 Oct 2021
2:50
AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer
Eric Pujade-Lauraine • 26 Sep 2015

Related Videos

4:28
Update on PETRA trial investigating a next-generation PARP1 select inhibitor
Timothy Yap • 13 Apr 2022
3:05
Investigating the ATR inhibitor elimusertib in advanced solid tumors
Timothy Yap • 13 Apr 2022
2:22
TRESR trial: Investigating an ATRi in patients with DNA damage repair loss-of-function mutant tumors
Timothy Yap • 13 Apr 2022
0:50
Combinatorial PARPi therapies in advanced endometrial cancer
Benoit You • 11 Apr 2022
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals